Blog
RSS FeedPosted by Michael Wonder on 11 Oct 2022
Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma
11 October 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 10 Oct 2022
Mental health funding of £1.8 million welcomed by NICE and MHRA to explore regulation of digital mental health tools
10 October 2022 - NICE and the MHRA have been awarded £1.8 million funding by Wellcome over three years to explore ...
Posted by Michael Wonder on 06 Oct 2022
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant
28 September 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using maribavir ...
Posted by Michael Wonder on 06 Oct 2022
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
28 September 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Oct 2022
Ozanimod hydrochloride for treating moderate to severe active ulcerative colitis
5 October 2022 - NICE has published evidence based recommendations on the use of ozanimod hydrochloride for the treatment of ...
Posted by Michael Wonder on 05 Oct 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
5 October 2022 - NICE has published evidence based recommendations on the use of azacitidine for the maintenance treatment of ...
Posted by Michael Wonder on 30 Sep 2022
NICE review does not recommend routine funding for Duchenne muscular dystrophy gene therapy ataluren in draft guidance
30 September 2022 - NICE has today published draft guidance for public consultation which does not recommend ataluren (Translarna, PTC Therapeutics) ...
Posted by Michael Wonder on 28 Sep 2022
News “hyperbole” in Government media releases on new drugs can undermine confidence in NHS, says editor
28 September 2022 - Phrases such as “cutting edge,” “game changing,” and “ground breaking” have no place in the description ...
Posted by Michael Wonder on 28 Sep 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
28 September 2022 - NICE has published evidence-based recommendations on the use of atezolizumab for adjuvant treatment of adults with ...
Posted by Michael Wonder on 27 Sep 2022
NICE recommends NHS collects real world evidence on devices that monitor people with Parkinson’s disease
27 September 2022 - Five promising technologies that could help improve symptoms and quality of life for people with Parkinson’s disease ...
Posted by Michael Wonder on 23 Sep 2022
1,500 people set to receive new skin cancer treatment that reduces the risk of it returning and spreading
23 September 2022 - Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab (also ...
Posted by Michael Wonder on 23 Sep 2022
NICE approves routine use of drug combination for advanced breast cancer
23 September 2022 - Another life-extending drug combination for some people with advanced breast cancer will now be available for routine ...
Posted by Michael Wonder on 23 Sep 2022
Vedolizumab for the treatment of patients with chronic refractory pouchitis
21 September 2022 - NICE is unable to make a recommendation about the use in the NHS of vedolizumab for the ...
Posted by Michael Wonder on 20 Sep 2022
NICE recommends BeiGene’s Brukinsa (zanubrutinib) for patients with Waldenström’s macroglobulinaemia who have had at least one treatment
19 September 2022 - Brukinsa Is the first Bruton’s tyrosine kinase inhibitor recommended by NICE for routine use for Waldenström’s macroglobulinaemia. ...
Posted by Michael Wonder on 15 Sep 2022
Advicenne updates on availability of Sibnayal to patients and caregivers in Great Britain
14 September 2022 - Sibnayal has been accepted for use within NHS Scotland. ...